Navigation Links
Lorus Advances Clinical Development of GTI-2040 Combined with Ara-C in Acute Myeloid Leukemia
Date:8/29/2007

strong antitumor and antimetastatic activity in a variety of tumor types in both in vivo and in vitro models and is under study in a multiple Phase I/II clinical program. R2 has been described as a malignant determinant that is elevated in a wide range of tumors, which can cooperate with a variety of cellular cancer causing genes known as oncogenes to enhance tumor growth and metastatic potential.

About Lorus

Lorus is a biopharmaceutical company focused on the research and development of novel therapeutics in cancer. Lorus' goal is to capitalize on its research, preclinical, clinical and regulatory expertise by developing new drug candidates that can be used, either alone, or in combination with other drugs, to successfully manage cancer. Through its own discovery efforts and an acquisition and in-licensing program, Lorus is building a portfolio of promising anticancer drugs. Lorus Therapeutics Inc. is listed on the Toronto Stock Exchange under the symbol LOR, and on the American Stock Exchange under the symbol LRP.

Forward-Looking Statements

This press release may contain forward-looking statements within the meaning of Canadian and U.S. securities laws. Such statements include, but are not limited to, statements relating to: our research program plans, our plans to conduct clinical trials, the successful and timely completion of clinical studies and the regulatory approval process, our ability to fund future research, our plans to obtain partners to assist in the further development of our product candidates, the establishment of corporate alliances, the Company's plans, objectives, expectations and intentions and other statements including words such as "continue", "believe", "plan", "expect", "intend", "will", "should", "may", and other similar expressions. Such statements reflect our current views with respect to future events and are subject to risks and uncertainties and are necessarily based upon a number of estimates and assumptions
'/>"/>

SOURCE Lorus Therapeutics Inc.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. The Affymetrix GeneChip Scanner 3000 New Advances in Scanner Design for Superior Performance, Reliability, and Dynamic Range
2. Quintessence Biosciences advances cancer drug
3. Healthcare slow to adopt genetic advances
4. Wireless advances in Madison, heats up in Waukesha
5. GE Healthcares CT Scanner advances coronary imaging
6. Cancer treatment advances as trials show no harm to mice
7. New CT scanner by GE Healthcare advances imaging technology
8. Small wonders: Intersection of biotech and nanotech will produce big advances
9. Standards Needed for Advances in Healthcare Technology
10. BioRobot MDx standardize your automated protocols in clinical laboratories
11. What patients want: A story of choice, clinical trials & evidence-based medicine
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... Toronto, Canada (PRWEB) July 31, 2014 ... with some of the first transcriptome-wide analyses appearing ... a standard assay for RNA measurement. In the ... high throughput, more specific, work with smaller input ... special tissues (eg, blood samples). On the bioinformatics ...
(Date:7/31/2014)... Miami, Fla. (PRWEB) July 31, 2014 The ... for distribution of its monthly news magazine, Kidney Cancer News. ... have a presence on a website maintained by an international ... noted an immediate increase in viewers.” , This month’s program ... of kidney tumors analyzed in a recent study. Kidney ...
(Date:7/30/2014)... and PARIS , July 30, ... (EURONEXT: SAN and NYSE: SNY) today announced that the ... Administration (FDA) rare pediatric disease priority review voucher in ... alirocumab.  The priority review voucher entitles the holder to ... an expedited 6-month review from the filing date instead ...
(Date:7/30/2014)...  The Chicago Bears are excited to announce the ... in an effort to raise awareness of skin cancer. ... SPOT me™ skin cancer screenings at a preseason fan ... SPOT me™ is an educational campaign designed to inform ... of skin cancer, and encourages people to get screened ...
Breaking Biology Technology:The Evolution of RNA-Sequencing, Upcoming Live Webinar August 22 hosted by Xtalks 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 2Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 3Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 4Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 5Regeneron and Sanofi Announce Plan to Use Priority Review Voucher For Alirocumab U.S. FDA Submission 6Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 2Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 3Chicago Bears Join the American Academy of Dermatology in Fight against Skin Cancer 4
... N.Y., Sept. 5 BioSpecifics,Technologies Corp. (OTC Bulletin ... collagenase based products, announced today that,it has signed ... related,to its future royalty obligations for Peyronie,s disease ... one-time cash payment., BioSpecifics has modified its ...
... 4 Hologic, Inc.,(Nasdaq: HOLX ) today announced ... the Morgan Stanley Global Healthcare Unplugged,Conference being held September ... NY., Interested parties are invited to listen to ... September 9, 2008, at 1:35 PM.,Eastern Time on the ...
... COLLINS, Colo., Sept. 4 InVitria,( ... of animal free,products that enhance productivity, ... companies,in the biopharmaceutical, cell culture, life ... Sponsorship of Cambridge Healthtech,Institute,s 4th Annual ...
Cached Biology Technology:BioSpecifics Technologies Corp. Buys Down Royalties for Peyronie's Disease 2Hologic to Present at the Morgan Stanley Global Healthcare Unplugged Conference 2InVitria Sponsors Cambridge Healthtech's Optimizing Cell Culture Development Conference 2
(Date:7/31/2014)... have completed a 20-year study that looks at ... different times of the year. It finds that ... frame has no measurable negative consequences for the ... , The study was conducted by Gene Towne, ... fire chief, and Joseph Craine, research assistant professor, ...
(Date:7/31/2014)... experimental vaccine protected 100 percent of animal models against ... , which causes an intestinal disease that kills approximately ... print in Infection and Immunity . , ... non-human primates against the purified toxins produced by ... spore infection, a laboratory model that mimics the human ...
(Date:7/31/2014)... Edmond Becquerel first discovered the photovoltaic effect in 1839, ... power of sunlight for its own purposes. In a ... of the FASEB Journal , scientists ... power of sunlight by focusing on a naturally occurring ... evolution. This conservationor persistence over time and across speciessuggests ...
Breaking Biology News(10 mins):Study finds benefits to burning Flint Hills prairie in fall and winter 2Study finds benefits to burning Flint Hills prairie in fall and winter 3C. difficile vaccine proves safe, 100 percent effective in animal models 2Scientists shine bright new light on how living things capture energy from the sun 2
... that previously unrecognized substances released by algae blooms have ... interfere with the normal activity of reproductive hormones. The ... as potentially harmful to humans and aquatic animals, but ... are calling for a revision of environmental monitoring programs ...
... the establishment of the Jeffrey Modell Endowed Chair in ... at the Hospital,s Ruth and Tristram Colket, Jr. Translational ... pediatric immunologist Jordan S. Orange, M.D., Ph.D. The chair,s ... new ground in his ongoing research. Dr. Orange is ...
... the brain are characteristic features of Alzheimer disease. The ... that plays a central role in learning and memory, ... effect of tau protein is largely eliminated when the ... Max Planck Research Unit for Structural Molecular Biology at ...
Cached Biology News:Modell Chair in Pediatric Immunology established 2Tau-induced memory loss in Alzheimer's mice is reversible 2Tau-induced memory loss in Alzheimer's mice is reversible 3
Coverslips for Microarrays, 1. *Category: MICROARRAY ACCESSORIES....
S. O'Hare & C.K. Atterwill • In vitro toxicity techniques for regular lab use. Ex vivo techniques are also covered with the aim of reducing and refining the use of animals in the future....
... 2'-O-Methyltransferase converts Cap 0 (or Cap 0-like) ... 1 structure has been shown to increase ... 50%. This improvement is seen in Cap ... Capping System as well as those Cap ...
Form: Concentrated Applications: ELISA...
Biology Products: